Discover insights into the Global Metered Dose Inhaler Devices Market, projected to grow at a high CAGR during 2024-2031. Advancements in technology, rising investments in R&D, and increasing prevalence of respiratory disorders such as asthma and COPD are key drivers.
Table of Contents
Industry Overview
Metered Dose Inhaler Devices Market is estimated to grow at a high CAGR during the forecast period 2024-2031
A metered-dose inhaler (MDI) is a pressurized inhaler that delivers medication using a propellant spray. It is widely useful for people with respiratory disorders like asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, and emphysema.
For More Insights Request Free Sample
Market Trends
The market for metered dose inhalers is poised for growth, propelled by the increasing adoption of breathing-actuated inhalers and substantial investments in research and development.
Advancements in technology, coupled with a growing demand for metered dose inhalers, are key factors driving market expansion. Additionally, heightened research and development investments and a rise in chronic respiratory conditions such as asthma, COPD, and chronic bronchitis contribute to this growth. According to the World Health Organization (WHO), nearly 200 million individuals worldwide are affected by chronic obstructive pulmonary disease (COPD). Government organizations' increased funding for chronic disease treatment further accelerates market growth. For example, in the European Union, COPD's direct cost represents about 6% of total health expenditure, constituting approximately 56% of the total respiratory disease costs.
The adoption of metered dose inhalers is also bolstered by technological advancements. Increasing awareness among individuals about advanced respiratory devices, such as bronchodilator inhalers, which offer advantages over traditional treatments, further drives market expansion. Moreover, rising healthcare expenditures from both governmental and private sectors may lead to increased infrastructure investments, further stimulating the metered dose inhaler market.
Market growth is further supported by various product launches and research endeavors. For instance, Teva Pharmaceuticals, an affiliate of Teva Pharmaceutical Industries Ltd., announced groundbreaking study findings on May 17, 2022. These findings centered on the usage of short-acting beta agonists (SABA) and their established clinical thresholds, highlighting real-world applications in asthma patients in the U.S. Teva's introduction of the ProAir Digihaler (albuterol sulfate) inhalation powder, a digital inhaler, underscores the industry's commitment to innovation and advancing patient care.
For Customized Report: www.datamintelligence.com/customize/metered-dose-inhaler-devices-market
Market Segmentation
By Product Type
- Manually-Actuated Pressurized Inhalers
- Breath-Actuated Pressurized Inhalers
By Medications
- Corticosteroids
- Bronchodilators
- Combination (Corticosteroid & Bronchodilators)
By Application
- Chronic Obstructive Pulmonary Disease (COPD)
- Asthma
- Emphysema
- Chronic Bronchitis
- Bronchospasm
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Market Key Players
Major players are F. Hoffmann-La Roche, AstraZeneca, GSK plc, Pfizer Inc., Amgen Inc., Novartis AG, Boehringer Ingelheim GmbH, Cipla Inc., Merck & Co. Inc and Teva Pharmaceutical Industries Ltd.
Trending Reports
Medical Suction Devices Market
Inhalation Therapy Nebulizer Market
